Efficacy of Various Antidiabetic Agents as Add-On Treatments to Metformin in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis

Table 3

Summary of FPG (mg/dL) between the treatment and the control groups.

Study	Treatment				Control				Difference
	n	Baseline	Final	Change	n	Baseline	Final	Change	between groups
				TZDs versus DPP IV inhs.
(i) Scott et al. [22]; Rosiglitazone versus Sitagliptin	87	156.9 ± 31.6	132.8 ± 29.9	−24.5 ± 33.55	92	157.2 ± 30.7	145.8 ± 35.3	−11.7 ± 33.52	−12.8
(ii) Bolli et al. [23]; Pioglitazone versus Vildagliptin	295	198.20 ± 48.65; (11.0 ± 2.7 mmol/L)	NA	−28.83 ± 48.95; (−1.6 mmol/L)	280	198.40 ± 46.85; (11.3 ± 2.6 mmol/L)	NA	−18.02 ± 49.22; (−1.0 mmol/L)	−10.81
				TZDs versus SUs
(i) Charbonnel et al. [24]; Pioglitazone versus Gliclazide	317	212.61 ± 55.86; (11.8 ± 3.1 mmol/L)	NA	−32.43 ± 59.28; (−1.8 ± 0.18 (SE) mmol/L)	313	203.60 ± 46.85; (11.3 ± 2.6 mmol/L)	NA	−19.82 ± 57.30; (−1.1 ± 0.18 (SE) mmol/L)	−12.61
(ii) Garber et al. [25]; Rosiglitazone versus Glibenclamide	152	188.95 ± 36.32	151.05 ± 43.16	−36 ± 40.18^a	153	193.68 ± 34.21	143.27 ± 46.16	−46 ± 41.50^a	10
(iii) Umpierrez et al. [26]; Pioglitazone versus Glimepiride	107	184.2 ± 42.14	NA	−39.7 ± 35.38; (SE = 3.42)	96	180.4 ± 38.72	NA	−34.1 ± 35.57; (SE = 3.63)	−5.6
(iv) Hamann et al. [27]; Rosiglitazone versus Glibenclamide, Gliclazide	285	189.19 ± 50.45; (10.5 ± 2.8 mmol/L)	NA	−41.26 ± 48.67; (−2.29 ± 0.16 (SE) mmol/L)	288	183.78 ± 52.25; (10.2 ± 2.9 mmol/L)	NA	−40.54 ± 48.92; (−2.25 ± 0.16 (SE) mmol/L)	−0.72
				TZD versus TZD
(i) Derosa et al. [28]; Pioglitazone versus Rosiglitazone	48	161 ± 24	140 ± 15	−21 ± 21^a	48	164 ± 27	146 ± 18	−18 ± 23.81^a	−3

Data are mean ± SD values. NA: not available. ^aSD calculated from SD baseline and final values. To convert mg/dL to mmol/L multiply by 0.0555.